Abstract
Angiogenic factors released by cancer cells increase structurally and functionally abnormal tumor micro-vascularization, resulting in metastases and progressive disease. Such diffusible factors bind to specific receptors of endothelial cells and activate the angiogenic signal pathway. Treatments with antiangiogenic monoclonal antibodies (e.g., bevacizumab) or using small molecules with anti-tyrosine kinase activity (e.g., sunitinib, sorafenib, ZD6474, erlotinib, or thalidomide) can block angiogenic signaling, lower blood tumoral irrigation, and improve chemotherapy distribution. Numerous studies have shown that a combination of biotherapy and chemotherapy can improve medical management of patients with advanced or metastatic non-small cell lung carcinomas. Biotherapy combination approaches also yield encouraging results promoting the development of targeted antitumor drugs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
